Early data suggest that the antibody drug conjugate patritumab deruxtecan increases antitumor activity in early-stage breast cancer after a single dose.
Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers -; ATR inhibitor elimusertib and PARP inhibitor AZD5305 -; are safe and clinically beneficial in treating patients with advanced solid tumors.
Cairo, Egypt: In a new study conducted by Janet L. Kwiatkowski and team, it was seen that deferiprone had acceptable effectiveness and safety profiles, which were similar to those reported in.
Seven psychiatric groups are calling for the FDA to hold a public advisory committee meeting about its risk evaluation and mitigation strategy (REMS) for the schizophrenia drug clozapine.